Study of CPX-351 (VYXEOS) in Individuals Under 22 Years Old with Secondary Myeloid Neoplasms | Clinical Trial

Study of CPX-351 (VYXEOS) in Individuals Under 22 Years Old with Secondary Myeloid Neoplasms | Clinical Trial | Right2Hope